EGFR and non-small cell lung carcinoma: In preclinical A431 human epidermoid carcinoma, HT29 colorectal carcinoma, and Calu-6 NSCLC xenograft models, administration of motesanib in combination with the fully human anti-EGFR monoclonal antibody panitumumab resulted in greater antitumor activity than single-agent treatment [15].